Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD

• Mia Jensen,
• Steffen F. Nielsen,
• Steffen Thiel,
• Søren W.K. Hansen,
• Yaseelan Palarasah,
• Per Svenningsen,
• Jesper N. Bech,
• Frank H. Mose,
• Boye L. Jensen

Affiliations

Mia Jensen

Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Correspondence: Mia Jensen, Department for Molecular Medicine, Unit for Cardiovascular and Renal Research, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.

Steffen F. Nielsen

University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Steffen Thiel

Department of Biomedicine, Aarhus University, Aarhus, Denmark

Søren W.K. Hansen

Unit of Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark

Yaseelan Palarasah

Unit of Cancer and Inflammation Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark

Per Svenningsen

Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark

Jesper N. Bech

University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Frank H. Mose

University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Herning, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Boye L. Jensen

Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark